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A B S T R A C T
In the current study, twenty-two compounds based upon 3-hydroxy-3-(2-oxo-2-phenylethyl)indolin-2-one nu-
cleus were designed, synthesized and in vitro evaluated for HIV-1 RT inhibition and anti-HIV-1 activity.
Compounds 3d, 5c and 5e demonstrated encouraging potency against RT enzyme as well as HIV-1 in low
micromolar to nanomolar concentration with good to excellent safety index. Structure activity relationship
studies revealed that halogens such as bromo or chloro at 5th the position of oxindole ring remarkably enhanced
the potency against RT. Moreover, methoxy or chloro groups at the ortho position of phenyl ring also sig-
nificantly favored RT inhibition activity. Seven compounds (3b, 3c, 3d, 3e, 5b, 5c and 5e) with better anti-HIV-
1 potency were tested against the mutant HIV-1K103N strain. The putative binding mode, as well as interaction
patterns of the best active compound 5c with wild HIV-1 RT were studied via docking studies.
1. Introduction
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) act at
allosteric site of HIV-1 RT in a non-competitive manner and inhibits its
catalytic activity. Subsequently, inhibition of catalytic activity hampers
the synthesis of double-stranded DNA copy of the viral genome [1,2].
Central role of RT enzyme in the life cycle of HIV makes it an attractive
target and it has been exploited clinically for reduction of viral load
from serum [3]. NNRTIs are crucial component of the current anti-HIV
therapy named Highly Active Anti Retroviral Therapy (HAART), due to
their potent anti-viral activity, high specificity and low toxicity [4–6].
However, continuous emergence of drug resistance against clinically
used NNRTIs compromises their usefulness [7]. Resistance generally
arises due to single point or multiple mutations at the Non-Nucleoside
Inhibitory Binding Pocket (NNIBP) [8,9]. Among the patients receiving
NNRTIs therapy, mutations like K103N and K103N/Y181C in HIV-1 RT
are more frequently observed inside the NNIBP. In general, single
mutation in NNIBP like K103N is adequate in reduction of RT
sensitivity towards the first line drugs, while dual mutant strains
(K103N/Y181C) exhibit totally resistant against the first generation
NNRTIs and also reduced the efficacy of second generation NNRTIs
[10,11]. Overall, ever emerging problem of drug resistance against the
clinically available anti-HIV-1 drugs drive the need for search of new
drugs having improved efficacy against wild as well as mutant RT
strains with favourable pharmacokinetic profile.
Target based virtual screening techniques has made drug discovery
process fast, more economic and goal-oriented, such techniques have
been recognized as crucial tool in drug discovery and development
process [12–14]. Moreover, similar strategy has also been utilized for
the discovery of potential anti-HIV-1 agents [15–17]. In our previous
study, attempts were made for the search of NNRTIs using structure-
based virtual screening against wild and two mutant strains K103N and
K103N/Y181C. Finally, nine hits were shortlisted in the study which
exhibited significant in silico activity against three selected strains [18].
In another recently published report as an extension of the above
mentioned virtual studies, we synthesized and evaluated compounds
based on benzodiazepin-2-one nucleus against wild RT, the overall
study afforded two hits against wild RT with low micro molar potency
(> 10 μM) and good safety index (> 46). The finding of the above
study provokes our interest to explore more virtual screened hits for
anti-HIV-1 activity [19].
Despite the structural diversity of NNRTIs, they share common set of
pharmacophoric features, which consist of phenyl ring at one terminal
and an aromatic or hydrophobic wing at the second terminal, while at
the centre NNRTIs possess a hydrophilic linker like amide, thioamide or
glycinamide [20,21]. Phenyl or hydrophobic part of NNRTIs form hy-
drophobic interactions with the non-polar residues like Phe-227, Tyr-
181, Tyr-188, Trp-229 and Leu-234 of NNIBP, while central polar linker
interacts with the hydrophilic residues like Lys-101 and Lys-103 via
hydrogen bonding interactions [22,23].
In the current study, we selected one more hit based on 3-hydroxy-
3-(2-oxo-2-phenylethyl)indolin-2-one (3a, Fig. 1) from the virtual
screening studies [18] and decided to proceed for synthesis, RT in-
hibition and anti-HIV-1 evaluation studies. Through literature study
revealed that compounds containing the similar pharmacophoric fea-
tures are already reported as potential inhibitors of HIV-1 RT. In a si-
milar study, Williams and co-workers reported potential anti-HIV-1 RT
and anti-HIV activity of compound 5-Chloro-3-(phenylsulfonyl)indole-
2-carboxamide (A) with IC50 and EC95 of 3 nM [24]. In another report,
La Regina et al., synthesized and evaluated series of compounds in
which compound B showed potent activity against HIV-1 RT and HIV-1
with IC50 of 1.3 nM and EC50 of 8 nM, respectively [25]. Dousson and
team performed lead optimization studies of Aryl-Phospho-Indole as
HIV-1 NNRTIs, afforded compound C (IDX899) as potent inhibitor with
IC50 0.34 μM [26,27]. In another study, cyclopropyl-Indole based
compounds were designed and evaluated for HIV-1 RT activity, among
the series of compounds, D showed potent RT inhibitory potential with
IC50 0.066 μM [28]. Efavirenz (E), a clinically approved NNRTIs and its
structural analogue F possessed anti-HIV-1 and RT inhibition activity in
low nano molar concentration, both drugs bear benzoxazin-2-one
nucleus which shares pharmacophoric similarity with indole-2-car-
boxamide [29]. Another compound G based on benzoimidazol-2-one
with similar functionality was also found to be potent inhibitor of HIV-1
RT and HIV-1 with IC50 5 and EC50 2 nM, respectively [30].
Anti-HIV potential of the above reported compounds having similar
pharmacophoric features with the virtual screened hit (3a), encourage
us to explore its RT inhibition potential. Next, in order to explore
structure activity relationships (SARs), halogens like bromo, chloro and
without substitution (H) were tried at 5th position of oxindole ring,
while other hydrophobic wing (phenyl) was tried with different elec-
tron donating and withdrawing substituents (Scheme 1).
2. Results and discussion
2.1. Chemistry
To synthesize the target hit (3a), 5-bromoisatin and 4-fluoro acet-
ophenone were used as starting materials; different reaction conditions
(Table 1) were tried in order to standardize the reaction (Scheme 1).
Frist, DMF and potassium carbonate were used as solvent and base
respectively, after 4 h of stirring at room temperature, reaction mixture
showed multiple spots on TLC. Next, acetonitrile and triethylamine
were used, after heating the reaction mass at 80 °C for 3 h, multiple
spots were again observed on TLC, including some unreacted starting
material 5-chloroisatin. The spot having highest intensity on TLC was
purified using column chromatography and characterized using various
spectral techniques, which afforded 30% as desired product. Next, to
enhance the yield, solvent and base was replaced with ethanol and
diethyl amine, respectively and reaction mixture was stirred at room
temperature. After six hours, reaction ended-up as single spot and de-
sired compound 3a was obtained in 88% yield [31–35]. Rest of the
compounds 3b–5j were synthesized in good to excellent yield (78–96%)
using the optimized reaction conditions of compound a3. All the syn-
thesized compounds were characterized by spectral techniques like 1H
Fig. 1. Literature reported potential HIV-1 RT inhibitors (A–G) and virtual screening hit (3a).
NMR, 13C NMR, FTIR, ESI-MS and elemental analysis. Both enantiomers
of the compound 5c were separated by using chiral preparative HPLC.
2.2. Biological activity
2.2.1. In-vitro HIV-1 RT inhibition assay
Initially, synthesized virtual hit (3a) was tested for wild HIV-1 RT
inhibitory activity using RT assay kit (Roche). In the study, marketed
drug efavirenz was used as a reference positive control while 5% DMSO
was taken as negative control [36,37]. Virtual hit compound 3a dis-
played moderate inhibitory potential against HIV-1 RT with IC50 of
15.54 μM. In the next phase, keeping 5-bromo intact at oxindole system,
compounds without substitution (3b) as well as different substitutions
at phenyl ring (3c–f) were tested. Interestingly, compound without
substitution at phenyl ring 3b showed better potency (5.22 μM) than
the virtual hit 3a. Further, electron donating methyl and methoxy
groups at meta (3c) and ortho (3d) position enhanced the potency
(IC50= 1.38 and 0.82 μM, respectively). Furthermore, halogen chloro
group at ortho position (3e) also favored the inhibition potency
(2.03 μM), while bromo at meta position (3f) markedly decreased the
RT inhibition potency (32.37 μM). Further, to investigate the role of 5-
bromo at the oxindole ring on its RT inhibitory potential, compounds
4a–f were synthesized which possessed hydrogen instead of bromo and
subsequently tested against HIV-1 RT. Unfortunately, replacement of
bromo with hydrogen at oxindole was not found favorable for RT in-
hibition potency and except 4d, other compounds (4a, 4b, 4c, 4e and
4f) exhibited weak to least potency.
Next, compounds having 5-chloro at the oxindole ring and different
substitution at the phenyl ring (5a–j) were synthesized and evaluated
for RT inhibition activity. Compound 5a is a bioisoster of virtual hit 3a,
but in term of RT inhibition potential, it showed better activity
(IC50= 5.92 μM) than 3a. Further, replacement of para fluoro with
hydrogen significantly reduced its activity (27.26 μM) while substitu-
tion with 2-methoxy (5c) markedly increased the potency (0.27 μM),
moreover compound 5c was found to be the most potent among the all
tested compounds. In contemporary to this, methoxy at meta position
(5d) drastically reduced the activity. Among halogen substituted com-
pounds, chloro at ortho position (5e) favored the RT inhibition activity
(0.76 μM) while, chloro as well as bromo at meta position (5f and 5 g)
was found unfavorable. Compounds with stronger electron with-
drawing nitro group at meta position (5h) and compounds having di-
substitution with methoxy and chloro (5i and 5j) also showed weak
activity (see Table 2).
Overall, SAR studies revealed that halogens like bromo and chloro
at 5th position of oxindole ring is crucial for RT inhibition activity,
further, methoxy or chloro groups at ortho position of phenyl ring sig-
nificantly favored their RT inhibition activity (Fig. 2).
2.2.2. Evaluation of anti-HIV-1 activity and cytotoxicity
All the synthesized compounds 3a–5j were evaluated for anti-HIV-1
activity against wild strain HIV-1IIIB in T lymphocyte cells by syncytia
formation assay. The assay is based upon the cytopathic effect (CPE) of
HIV-1 and measured the viability of HIV-1 infected T lymphocyte cells
[38]. The cytotoxicity of the synthesized compounds on T cell lines was
also assessed by MTT colorimetric assay method [39].
Among the compounds having bromo substitution at oxindole ring
(3a–f), virtual hit 3a and compound 3f showed weak potency while
four compounds (3b, 3c, 3d and 3e) showed superior potency with
EC50< 11 μM. It is worthy to note that all four compounds (3b, 3c, 3d
and 3e) also showed low micromolar potency against HIV-1 RT.
Moreover, compound 3d exhibited sub-micromolar potency against
HIV-1 (EC50= 0.19 μM) as well as HIV-1 RT (IC50= 0.82 μM) with
selectivity index>2105. Among the compounds 4a–f, none of the
compounds showed superior activity against HIV-1 RT, in similar pat-
tern all the compounds showed weak or least activity against HIV-1
also. Compounds bearing 5-chloro at oxindole ring (5a–5j), displayed
weak to potent activity against HIV-1. Three compounds 5b, 5c and 5e
displayed low micromolar potency, particularly compound 5c having
methoxy substitution at ortho position exhibited nano molar potency
(0.090 μM) against HIV-1 with selectivity index> 4444. Further,
compound 5f having meta chloro substitution exhibited moderate anti-
HIV-1 activity (14.51 μM), while rest of the compounds (5a, 5d, 5g, 5h,
5i and 5j) showed weak to least activity. Overall, with few exceptions,
most of the compounds showed good to excellent co-relation between
RT inhibition and anti-HIV-1 activity (see Table 2).
Scheme 1. Synthetic route for the titled compounds (3a–5j).
Table 1
Optimization of the reaction conditions to obtain hit compound 3a.
S. No Solvent Base Reaction
condition
Inference
a1 DMF K2CO3, (2 Eq.) rt, 4 h Multiple spots (not isolated)
a2 ACN Et3N, (2 Eq.) heating, 80 °C,
3 h
30% yield (after column
purification)
a3 EtOH Et2NH,
(1.2 Eq.)
rt, 6 h 88% yield, single spot
reaction
Table 2
Results of HIV-1 RT inhibition, anti-HIV-1 and cytotoxicity evaluation.
Comp. Code Structure HIV-1 RT inhibition activity
(IC50)a
Anti-HIV-1 activity
(EC50)
Cytotoxicity (CC50)b Selectivity Index (SI, EC50/
CC50)
3a 15.54 μM 45.47 μM >400 μM >8.80
3b 5.22 μM 9.82 μM 157.20 μM 16.01
3c 1.38 μM 5.71 μM >400 μM >7 0.05
3d 0.82 μM 0.19 μM >400 μM >2105.26
3e 2.03 μM 10.79 μM 122.03 μM 11.31
3f 32.37 μM 38.96 μM 144.98 μM 3.72
(continued on next page)
Table 2 (continued)
Comp. Code Structure HIV-1 RT inhibition activity
(IC50)a
Anti-HIV-1 activity
(EC50)
Cytotoxicity (CC50)b Selectivity Index (SI, EC50/
CC50)
4a 82.61 μM 216.43 μM >400 μM >1.85
4b >100 μM 259.71 μM >400 μM >1.54
4c 62.37 μM 177.85 μM >400 μM >2.25
4d 14.18 μM 41.29 μM >400 μM >9.69
4e 69.68 μM 164.42 μM >400 μM >2.43
4f >100 μM 227.46 μM >400 μM >1.76
(continued on next page)
Table 2 (continued)
Comp. Code Structure HIV-1 RT inhibition activity
(IC50)a
Anti-HIV-1 activity
(EC50)
Cytotoxicity (CC50)b Selectivity Index (SI, EC50/
CC50)
5a 5.92 μM 59.58 μM 124.40 μM 2.09
5b 27.26 μM 8.45 μM >400 μM >47.33
5c 0.27 μM 0.090 μM >400 μM >4444.44
5d 51.31 μM 50.11 μM >400 μM >7.98
5e 0.76 μM 1.76 μM >400 μM >227.27
5f 34.25 μM 43.31 μM >400 μM >9.24
(continued on next page)
Anti-HIV-1 activity studies of compounds (3b, 3c, 3d, 3e, 5b, 5c, 5c
levo, 5c dextro and 5e) against the mutant HIV-1K103N strain, revealed
that all compounds exhibited weak activity. Although, compounds 3d
and 5c displayed comparatively better activity (EC50= 74.70 and
75.33 μM) compared to rest of the compounds (Table 3). Particularly,
the dextro enantiomer of compound 5c exhibited better potency
(EC50= 54.30 μM) compared to its levo enantiomer
(EC50= 147.18 μM) against the HIV-1K103N strain.
2.3. Docking studies
In order to explore the putative binding pattern of the best active
compound 5c inside NNIBP of HIV-1 RT, docking studies were per-
formed. Further, reference drug efavirenz was also made to dock under
similar conditions. The docked view of best scoring pose of compound
5c (Fig. 3) was found to be quite similar to binding mode of reference
drug efavirenz, for example, cyclopropyl moiety of efavirenz showed
prominent hydrophobic interactions with residues like Trp-229, Tyr-
188, Tyr-181 and Leu-237 (Fig. S1, supplementary information). In si-
milar fashion, 2-methoxyphenyl moiety of compound 5c showed si-
milar prominent interactions with above mentioned residues and also
with residue Phe-227 additionally [Fig. 3]. Furthermore, functionalities
like eC]O and eNH of oxazinone ring in efavirenz showed hydrogen
bonding interaction with Lys-101, in the same way eNH of oxindole
ring in compound 5c also exhibited similar interaction with Lys-101.
Further, chlorophenyl entity of compound 5c showed hydrophobic in-
teractions with residues like Val-106 and Tyr-318, corresponding to
this, phenyl ring of efavirenz showed similar interaction with both re-
sidues. Overall, compound 5c shared pharmacophoric similarity with
efavirenz and also exhibited similar binding pattern with HIV-1 RT that
may be responsible for its firm binding with HIV-1 RT and subsequently
for potent RT inhibition and anti-HIV-1 activity during the in vitro
assay.
Table 2 (continued)
Comp. Code Structure HIV-1 RT inhibition activity
(IC50)a
Anti-HIV-1 activity
(EC50)
Cytotoxicity (CC50)b Selectivity Index (SI, EC50/
CC50)
5g 62.14 μM 25.87 μM 146.69 μM 5.67
5h 58.51 μM 37.84 μM 121.10 μM 3.20
5i 73.08 μM 61.91 μM >400 μM >6.46
5j 68.86 μM 28.47 μM 118.94 μM 4.18
Efavirenz 0.057 μM
Zidovudine 0.0071 μM 5201.13 μM 732553.53
Lamivudine 0.1690 μM >1000 μM >5917.16
a Value is average of at least two independent experiment, relative standard deviation (RSD) was found within±15%.
b The symbol ‘> ’ indicated the compound still non-cytotoxic at the highest concentration was tested.
3. Experimental
3.1. Chemistry
All starting materials and reagents purchased from Sigma or SD fine
companies were used as received without further purification. Ethyl
acetate and hexane mixture (40:60) was used as mobile phase for thin
layer chromatography in order to monitor the progress of reaction.
Melting points were uncorrected and determined in open capillary
tubes using melting point apparatus, Precision Buchi B530 (Flawil,
Switzerland) containing silicon oil. The IR spectra of the synthesized
compounds were recorded using FTIR spectrophotometer (Shimadzu IR
Prestige 21, Shimadzu, Mumbai, India). 1H and 13C NMR spectra were
recorded on Bruker DPX-400 spectrometer (Bruker India Scientific Pvt.
Ltd., Mumbai, India) using TMS as an internal standard (chemical shifts
in δ). Elemental analysis was performed on Vario EL III M/s Elementar
C, H, N and S analyzer (ElementarAnalysensysteme GmbH, Hanau,
Germany). ESI-MS were recorded on MICROMASS Quattro-II LCMS
system (Waters Corporation, Milford, USA).
3.1.1. General procedure for the synthesis of 3a-5j compounds using
optimized reaction condition (a3)
Selected acetophenones (2a–k, 2 mmol) was stirred in ethanol
(15ml) containing diethylamine (2.4 mmol, 0.32ml) for 20min at
room temperature, then starting material respective isatins (1a–c,
2 mmol) was added slowly in portions. Further, the reaction mass was
stirred at room temperature (5–9 h) till completion as per TLC. After
completion of reaction, ethanol was evaporated on rotary evaporator to
half of its original volume and 15ml of ice cold water was added to the
reaction mixture. Resulting precipitates were filtered using vacuum
filtration and twice washed with cold ethanol (2× 10ml), followed by
diethyl ether (10ml) and finally dried in oven at 45 °C to get desired
compounds 3a–5j [31–35]. Synthesized compounds were first char-
acterized using non-spectral techniques like TLC and melting point and
then by different spectral techniques like IR, 1H NMR, 13C NMR, ESI-MS
and elemental analysis. Spectral data of the synthesized compounds are
given in the supplementary part of the manuscript.
3.1.2. Enantiomer separation of compound 5c
The enantiomers of compound 5c were separated by preparative
Fig. 2. Hit optimization studies from virtual hit 3a.
Table 3
Results of mutant anti-HIV-1K103N strain of selected compounds.
Number Experiment Method EC50 (μM)a
3b Inhibition of HIV-1 p24 antigen production ELISA 131.98
3c Inhibition of HIV-1 p24 antigen production ELISA >200.00
3d Inhibition of HIV-1 p24 antigen production ELISA 74.70
3e Inhibition of HIV-1 p24 antigen production ELISA 184.46
5b Inhibition of HIV-1 p24 antigen production ELISA 176.55
5c (racemic) Inhibition of HIV-1 p24 antigen production ELISA 75.33
5c (levo) Inhibition of HIV-1 p24 antigen production ELISA 147.18
5c (dextro) Inhibition of HIV-1 p24 antigen production ELISA 54.30
5e Inhibition of HIV-1 p24 antigen production ELISA 129.33
NVP Inhibition of HIV-1 p24 antigen production ELISA 5.38
a Value is the mean of three independent experiments.
HPLC using the chiral stationary phase (S,S)-Whelk-O1 dimensions
250×10mm and mixture of hexane, ethanol dichloromethane as sol-
vent in the ratio of 60: 20: 20, respectively. Detail of the method used
for enantiomer separation is given in the supplementary part of
manuscript.
3.2. In-vitro HIV-1 RT inhibitory assay
Titled compounds were in vitro evaluated via ELISA based colori-
metric assay using RT kit (Roche diagnostics). In the assay marketed
drug efavirenz was used as reference positive control. Procedure fol-
lowed during the assay is briefly described here; the reaction mixture
was set with template primer complex, RT enzyme and dNTPs in a lysis
buffer with or without inhibitors. The reaction mixture was incubated
at 37 °C for 1 h and then transferred to streptavidine-coated microtitre
plate (MTP). The biotin-labeled dNTPs that were incorporated in the
template due to activity of RT, bound to streptavidine. The unbound
dNTPs were washed using wash buffer and anti-DIG-POD was added to
the MTP. The DIG-labeled dNTPs incorporated in the template were
bound to an anti-DIG-POD antibody. The unbound anti-DIG-POD was
washed again with washing buffer and the peroxide substrate (ABST)
was added to the MTP. A colored reaction product was produced due to
the cleavage of the substrate catalyzed by peroxide enzyme. The ab-
sorbance of the sample was determined as an optical density (OD) at
405 nm using a micro titer plate ELISA reader [36,37]. The final value
of OD taken was average of duplicate results and% inhibition of HIV-1
RT was calculated using the below mentioned formula and IC50 was
calculated via further double dilutions.
= −⎛
⎝
× ⎞
⎠
%Inhibition 100 OD at 405 nm with inhibitor
OD at 405 nm without inhibitor
100
3.3. Anti-HIV-1 activity and cytotoxicity
The inhibitory effect of compounds on acute HIV-1IIIB infection was
measured by syncytia formation assay. In the presence or absence of
various concentrations of samples, exponentially growing C8166 cells
were infected with HIV-1IIIB at an appropriate multiplicity of infection
(MOI) and cultured in 96-well plates at 37 °C in 5% CO2 for 3 days. AZT
was used as positive control. At 3 days post-infection, the cytopathic
effect (CPE) was measured by counting the number of syncytia (mul-
tinucleated giant cell) in each well of 96-well plates under an inverted
microscope (100×). The inhibitory percentage of syncytia formation
was calculated by the percentage of syncytia number in sample treated
culture compared to that in infected control culture [38]. Seven com-
pounds (3b, 3c, 3d, 3e, 5b, 5c and 5e) which displayed encouraging
potency against wild strains of HIV-1 (EC50≤ 10.79 μM) were tested
against the mutant HIV-1K103N strain. Moreover, both enantiomers
(levo and dextro) of compound 5c were also tested against the mutant
HIV-1K103N strain (detailed method is given supplementary informa-
tion).
The cellular toxicity of compounds on C8166 cells was also assessed
by MTT colorimetric assay, which is based on the reduction of yellow
colored MTT by mitochondrial dehydrogenase of metabolically active
cells to a blue-purple formazan that can be dissolved in 50% DMF-15%
SDS. After the formazan was dissolved completely, the plates were
analyzed by Bio-TekELx 800 ELISA reader at 570 nm/630 nm [39].
According to the method described by Reed & Muench, 50% cyto-
toxic concentration (CC50) and 50% effective concentration (EC50) was
determined from dose–response curve. Selectivity index (SI) of anti-
HIV-1 activity is CC50/EC50.
3.4. Docking studies
Docking studies of the best active compound 5c and reference drug
efavirenz were performed against wild HIV-1 RT using Glide 5.9 in
extra precision mode, running on maestro version 9.4 [40]. Enzyme in
complex with co-crystallized ligand (rilpivirine) was retrieved from
Protein Data Bank (PDB ID: 3MEE) and prepared using protein pre-
paration wizard of Schrödinger suite [41]. Protein was pre-processed
separately by deleting the substrate co-factor as well as the crystal-
lographically observed water molecules (water without H bonds), fol-
lowed by optimization of hydrogen bonds. After assigning charge and
protonation state, finally energy was minimized with Root Mean Square
Fig. 3. Docked pose of compound 5c inside the NNIBP of 3MEE enzyme, showing hydrophobic and hydrogen bonding interactions represented by green and pink
dotted lines, respectively.
Deviation (RMSD) value of 0.30 Å using Optimized Potentials for Liquid
Simulations-2005 (OPLS-2005) force field [42]. Finally, energy mini-
mized protein and co-crystallized ligand was employed to build energy
grids within a cubic box around the centroid of the X-ray ligand pose.
The structures of the compound 5c, efavirenz and rilpivirine were
drawn using ChemSketch and converted to 3D structure with the help
of 3D optimization tool. By using LigPrep 2.6 module, the drawn li-
gands were geometry optimized; partial atomic charges were computed
using OPLS-2005 force field [43]. Finally, 32 poses were included with
different tautomeric and steric features for docking studies. Finally,
prepared ligands were docked with prepared protein using Glide 5.9
module, in extra precision mode (XP). The best docked pose (with
lowest Glide score value) obtained from Glide was analyzed. The value
of Root-Mean-Square Deviation (RMSD) between the X-ray binding
pose in protein–ligand complex and re-docked pose was found to be
0.62, which demonstrated the accuracy and reliability of the docking
protocol (Fig. S2, supplementary sheet).
4. Conclusion
In conclusion, series of twenty-two compounds was synthesized
based on the pharmacophoric features of virtual screened hit and sub-
sequently studied for HIV-1 RT inhibition, anti-HIV-1 activity and cy-
totoxicity. Among the all compounds, seven compounds (3b, 3c, 3d,
3e, 5a, 5c and 5e) inhibited the activity of HIV-1 RT with IC50 < 6 μM,
in which 3d, 5c and 5e displayed sub-micromolar potency with IC50 of
0.27, 0.76 and 0.82 μM, respectively. SAR studies revealed that halo-
gens like bromo or chloro at 5th position of oxindole ring is crucial for
HIV-1 RT inhibition activity and methoxy or chloro groups at ortho
position of phenyl ring also significantly favored RT inhibition activity.
Six compounds (3b, 3c, 3d, 5b, 5c and 5e) displayed encouraging anti-
HIV-1 activity with EC50 < 10 μM, particularly, three compounds 3d,
5c and 5e were found to be potently active against HIV-1 RT as well as
HIV-1 in low to sub-micromolar range with good to excellent safety
index. Majority of the compounds showed good to excellent co-relation
between HIV-1 RT inhibition activity and anti-HIV-1 activity. Current
study afforded compound 5c which possessed sub-micromolar
(0.27 μM) and nanomolar (90 nM) potency against HIV-1 RT and HIV-1,
respectively with excellent safety index (> 4444). Compounds 3b, 3c,
3d, 3e, 5b, 5c, 5clevo, 5cdextro and 5e were found be weakly active
against mutant HIV-1K103N strain. Although, the dextro enantiomer of
compound 5c showed better potency (EC50= 54.30 μM) compared to
its levo enantiomer (EC50= 147.18 μM). Compound 5c shared phar-
macophoric similarity as well as binding pattern with efavirenz that
may be accounted for its firm binding with wild HIV-1 RT and subse-
quently for potent RT inhibitory activity. Overall, study can be helpful
for de novo designing of HIV-1 RT inhibitor or further lead optimization
study to find more potent and safe anti-HIV-1 agents.
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